Outlook Wealth Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Outlook Wealth Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 12,628 shares of the company’s stock after buying an additional 353 shares during the period. Outlook Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,998,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. First Citizens Financial Corp raised its stake in Johnson & Johnson by 8.1% in the third quarter. First Citizens Financial Corp now owns 8,599 shares of the company’s stock valued at $1,339,000 after buying an additional 645 shares during the last quarter. PineStone Asset Management Inc. boosted its stake in Johnson & Johnson by 190.5% in the 3rd quarter. PineStone Asset Management Inc. now owns 1,494,978 shares of the company’s stock worth $232,843,000 after purchasing an additional 980,297 shares in the last quarter. Buckingham Capital Management Inc. grew its position in Johnson & Johnson by 6.5% during the 3rd quarter. Buckingham Capital Management Inc. now owns 10,703 shares of the company’s stock worth $1,667,000 after purchasing an additional 651 shares during the last quarter. McKinley Carter Wealth Services Inc. increased its stake in Johnson & Johnson by 0.6% during the 3rd quarter. McKinley Carter Wealth Services Inc. now owns 18,860 shares of the company’s stock valued at $2,937,000 after purchasing an additional 114 shares in the last quarter. Finally, OneAscent Financial Services LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth $838,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ traded down $0.68 on Friday, reaching $146.14. The stock had a trading volume of 6,182,982 shares, compared to its average volume of 7,728,638. The business’s 50-day moving average price is $155.26 and its two-hundred day moving average price is $155.32. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market cap of $352.17 billion, a P/E ratio of 9.11, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.68 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is currently 29.68%.

Analyst Ratings Changes

Several research firms recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, April 15th. Morgan Stanley cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Royal Bank of Canada dropped their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.